Cisplatin (DDP) is a commonly used chemotherapy drug; however, the side effects associated with its use, particularly acute kidney injury (AKI), limit its clinical application. Puerarin is a natural flavonoid extracted from the Chinese medical herb Radix puerariae, which has
been reported to alleviate DDPinduced nephrotoxicity. However, the mechanisms underlying puerarin regulation on microRNA (miR)31mediated signaling pathways in AKI remain unknown. Thus, the present study aimed to investigate the function of puerarin in a DDPinduced AKI rat model via reverse
transcriptionquantitative PCR and western blot analyses. The results demonstrated that DDP upregulated the levels of miR31 in a concentrationdependent manner, both in vitro and in vivo. Furthermore, DDP significantly increased blood urea nitrogen and malondialdehyde content, serum
creatinine and histopathological changes, while significantly decreasing the expression levels of superoxide dismutase, catalase and glutathione Stransferase in kidney tissues. TUNEL and western blot analyses indicated that DDP increased the expression levels of apoptotic proteins and affected
the Numb/Notch1 signaling pathway, which is downstream of miR31. The effects induced by DDP were counteracted following treatment with puerarin. Taken together, the results of the present study suggest that puerarin exhibits a renal protective effect against DDPinduced AKI by upregulating
miR31 expression and inhibiting the Numb/Notch1 signaling pathway.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China
Department of Blood Transfusion, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China
Department of Blood Transfusion, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250033, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites